Bradley J. Monk
Highly rated in
Highly rated in
Check Dr. Bradley J. Monk's experience treating your condition:
About Dr. Bradley J. Monk

Bradley Monk is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Scottsdale, Arizona. Monk has been practicing medicine for over 34 years and is highly rated in 14 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Cervical Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Oophorectomy. He is licensed to treat patients in Arizona. Monk is currently accepting new patients.

His clinical research consists of co-authoring 287 peer reviewed articles and participating in 30 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Bradley J. Monk it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Bradley J. Monk accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health
  •  Oscar
  •  Medica
  •  Cigna
View 2 More Insurances +

Call to see if your plan is accepted.
10197 N 92nd St, Scottsdale, AZ 85258
Other Locations
Phoenix, AZ 85016
13555 W Mcdowell Rd, Goodyear, AZ 85395
Background & Education
Graduate Institution
University Of Arizona College Of Medicine, 1988
Obstetrics and Gynecology
Gynecologic Oncology
Obstetrics & Gynecology in AZ
Hospital Affiliations
Abrazo West Campus
Abrazo Arrowhead Campus
HonorHealth Deer Valley Medical Center
Abrazo Central Campus
St Josephs Hospital And Medical Center
Mercy Gilbert Medical Center
Banner Desert Medical Center
Banner - University Medical Center Phoenix
Yavapai Regional Medical Center - West
Banner Estrella Medical Center
Valleywise Health Medical Center
HonorHealth John C Lincoln Medical Center
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Phase II Trial of Capecitabine and Docetaxel in the Treatment of Advanced and Recurrent Cervical Cancer
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix
A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A)
View 17 Less Clinical Trials -

287 Total Publications

Reply to C. Marchetti et al.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors